ArticleOncology and therapy2021

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Barbara D Cruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.